Artiva Biotherapeutics Inc Dossier - Source-backed chat

Artiva Biotherapeutics Inc

ARTVNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.80

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.12Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $348.1M

Enterprise Value $57.6M

Shares Outstanding 48.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Artiva Biotherapeutics is a clinical-stage biotechnology company uniquely positioned to disrupt the autoimmune disease space with its off-the-shelf, non-genetically modified natural killer (NK) cell therapy, AlloNK (AB-101). By leveraging a strategic partnership with GC Cell, Artiva has established a highly scalable, cost-effective manufacturing platform that bypasses the complex, expensive, and patient-specific logistics of autologous CAR-T therapies. Initial clinical data released in May 2026 demonstrated a remarkable 71% ACR50 response rate at six months in highly refractory rheumatoid arthritis (RA) patients, with an exceptional safety profile showing no cases of CRS or ICANS. This clean safety profile supports outpatient administration in community rheumatology settings, vastly expanding the addressable market compared to hospital-bound CAR-T alternatives. With FDA alignment secured for a single Phase 3 registrational trial in refractory RA scheduled to initiate in H2 2026, and a massive $300 million capital raise completed in May 2026, Artiva possesses both the clinical momentum and the financial runway to advance its lead candidate toward a potential BLA submission in 2029.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$23.00

Mean target$35.80

High · most bullish analyst$41.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$23.0015%

The Phase 3 trial experiences enrollment delays or fails to replicate the high ACR50 response rates observed in earlier small-cohort trials. Unexpected safety signals emerge during larger-scale testing, such as late-onset toxicities or low-grade CRS, which compromise its outpatient administration profile and force inpatient monitoring, severely limiting its competitive advantage over CAR-T therapies.

Base CaseCentral scenario

$35.8060%

Matches the consensus mean

Artiva successfully initiates the Phase 3 registrational trial in refractory RA in H2 2026. The trial meets its primary endpoint of ACR50 at six months with efficacy comparable to initial Phase 2a data and maintains a clean safety profile supportive of outpatient use. The company progresses toward a BLA submission in 2029, supported by its strong cash position following the May 2026 capital raise.

Bull CaseUpside scenario

$41.0025%

AlloNK demonstrates superior efficacy and safety in the Phase 3 registrational trial, maintaining or exceeding the 71% ACR50 response rate at six months. Outpatient administration is widely adopted in community clinics, driving rapid market penetration. The company successfully expands AlloNK into broader B-cell driven autoimmune indications such as Sjögren's disease and systemic sclerosis, establishing AlloNK as the premier off-the-shelf B-cell depleting therapy.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated off-the-shelf allogeneic NK cell platform (AlloNK) that avoids the high cost, manufacturing delays, and complex logistics of autologous CAR-T therapies.
Strong initial clinical efficacy with a 71% ACR50 response rate in highly refractory RA patients with at least six months of follow-up.
Excellent safety and tolerability profile with zero cases of CRS or ICANS, enabling outpatient administration in community rheumatology settings.
Clear regulatory pathway with FDA alignment on a single Phase 3 registrational randomized controlled trial of approximately 150 patients.
Robust financial backing and capitalization following a $300 million underwritten public offering in May 2026.

Key Investment Risks

Clinical trial risk associated with replicating early-stage Phase 2a efficacy and safety results in a larger, randomized Phase 3 patient population.
Dependence on a single lead candidate (AlloNK) for near-to-mid-term valuation.
Reliance on GC Cell for exclusive manufacturing technology and raw material supply.
Intense competition from both established biologic therapies and emerging autologous/allogeneic cell therapies targeting autoimmune diseases.

Thesis Invalidation Triggers

Failure to initiate the Phase 3 registrational trial in refractory RA by the end of 2026.
Any clinical trial data release showing a significant drop in the ACR50 response rate below clinically meaningful thresholds.
Emergence of severe, treatment-related adverse events (such as Grade 3+ CRS or ICANS) that disqualify AlloNK from outpatient administration.
Regulatory holds or major protocol disputes with the FDA regarding the Phase 3 trial design.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.